| HOME >> MEDICINE >> TECHNOLOGY |
$
46,142$
37,499$
91,860$
74,268The following table reconciles the specific items excluded from GAAP other income and expense in the calculation of non-GAAP other income and expense from continuing operations for the periods shown below:THORATEC CORPORATIONReconciliation of GAAP to Non-GAAP Other Income and Expense(Unaudited)(in thousands) Three Months Ended Six Months Ended June 30, 2012July 2, 2011June 30, 2012July 2, 2011 Other income (expense) on a GAAP basis
$
88$
(1,279)$
819$
(3,404)Impact of ASC 470-20 (Debt)
-1,244-3,127 Other income (expense) on a non-GAAP basis
$
88$
(35)$
819$
(277)The following table reconciles the GAAP tax expense adjusted for the tax effect of the adjustments from GAAP net income to non-GAAP net income from continuing operations:THORATEC CORPORATIONReconciliation of GAAP to Non-GAAP Tax Expense(Unaudited)(in thousands) Three Months Ended Six Months Ended June 30, 2012July 2, 2011June 30, 2012July 2, 2011Tax expense on a GAAP basis
$
,096
32.7%
$
,195
33.9%$
22,326
32.5%
$
9,696
34.0%Share-based compensation expense
2,4691,5324,4783,236Amortization of purchased intangibles
1,0118792,0231,799Impact of adoption of ASC 470-20 (Debt)
-497-1,251Excess compensation limitations and other
(973)(397)(1,240)(1,002)Levitronix Medical FMV inventory adjustments
110-252-Levitronix Medical transaction costs
-557-559Tax expense on a non-GAAP basis
$
2,713
32.2%
$
4,263
34.2%$
27,839
32.7%
$
25,539
34.2%The following table reconciles the guidance on a GAAP basis and non-GAAP basis for the periods shown below:THORATEC CORPORATIONReconciliation of GAAP to Non-GAAP Forward-Looking Gui
'/>"/>
| SOURCE Thoratec Corporation Copyright©2012 PR Newswire. All rights reserved |